The Conversation (0)
March 17, 2025
21 May 2024
Cleo Diagnostics
Revolutionising Ovarian Cancer Diagnosis Through Accurate and Early Detection Keep Reading...
27 February
Appendix 4D and Half Yearly Accounts
Cleo Diagnostics (COV:AU) has announced Appendix 4D and Half Yearly AccountsDownload the PDF here. Keep Reading...
31 January
Quarterly activities and cashflow report
Cleo Diagnostics (COV:AU) has announced Quarterly activities and cashflow reportDownload the PDF here. Keep Reading...
09 December 2024
CLEO Further Expands Ovarian Cancer Trial with Siles Health
Cleo Diagnostics (COV:AU) has announced CLEO Further Expands Ovarian Cancer Trial with Siles HealthDownload the PDF here. Keep Reading...
26 November 2024
The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial
Cleo Diagnostics (COV:AU) has announced The Royal Women's Hospital Joins CLEO Ovarian Cancer TrialDownload the PDF here. Keep Reading...
13 November
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market.This allowance fortifies Cardiol's... Keep Reading...
05 November
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume... Keep Reading...
30 October
Appendix 4C and Quarterly Activities Report - September 2025
Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - September 2025Download the PDF here. Keep Reading...
30 October
Nextech3D.ai Reports Strong 20% Q2 Sequential Revenue Growth With Gross Margins of 88% For the Three Months Ended September 30, 2025 ("Q2 2026")
Key Year-over-Year Highlights:Gross Margin Expansion: Increased to 88%, up from 71%, representing a 17-point improvement.Operating Loss Reduced by 65%: Narrowed to $439,000, from $1.25 million in 2024.Net Loss Reduced by 63%: Improved to $482,000, compared to $1.31 million last year.Deferred... Keep Reading...
23 October
Biotech and Pharma Market Update: Q3 2025 in Review
The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public biotech indexes rallied above critical levels last seen in 2021, with the NASDAQ Biotech Index... Keep Reading...
23 October
Top 4 Canadian Biotech Stocks of 2025
Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.Here the Investing News Network profiles the five best-performing Canadian biotech stocks on... Keep Reading...
Latest News
Latest Press Releases
Syntheia Announces Shares for Debt Transaction
14 November
E-Power Provides Update on Management Changes
14 November
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00